Nexera X2 — X-ceptional insights - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nexera X2 — X-ceptional insights


Nexera X2 – X-ceptional insights

Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new Nexera X2 UHPLC system targets routine analysis and applications in highly regulated environments demanding complex system setups.

System flexibility
The system flexibility is based on software features which control multiple gradients in a single system. This enables automated solvent blending on each pump in a binary gradient setup. The software has been adapted to meet the requirements for use in highly regulated environments.

Stability
Stability in gradient use has been improved by pump side modifications. Furthermore, design changes on inlet valve and degassing unit minimize air bubbles passing through the flow line and reduce their negative effects on stability and performance. For addressing specific appli-cations, additional micro reactor based mixing devices can be selected accordingly. A newly designed low volume quaternary option reduces the system volume to meet UHPLC needs while enabling a better inter-system method transfer.

Sensitivity
The new SPD-M30A photodiode array detector is perfectly suited ultra-high sensitive applica-tions using a capillary cell with low dispersion. Total reflection and a high energy deuterium lamp guarantee a low noise level. A novel temperature control principle decreases baseline drift and offers improved reliability even under changing environment conditions. Together with ultra-high speed data acquisition, software features which maximize resolution on the PDA while enabling peak deconvolution squeeze the maximum information out of a single analysis.

For more information please visit www.shimadzu.eu.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here